BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 20709477)

  • 1. Pharmacogenetics in palliative care.
    Kleine-Brueggeney M; Musshoff F; Stuber F; Stamer UM
    Forensic Sci Int; 2010 Dec; 203(1-3):63-70. PubMed ID: 20709477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized therapy in pain management: where do we stand?
    Stamer UM; Zhang L; Stüber F
    Pharmacogenomics; 2010 Jun; 11(6):843-64. PubMed ID: 20504256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic factors in pain and its treatment.
    Stamer UM; Stüber F
    Curr Opin Anaesthesiol; 2007 Oct; 20(5):478-84. PubMed ID: 17873601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics in pain management: the clinical need.
    Webster LR
    Clin Lab Med; 2008 Dec; 28(4):569-79. PubMed ID: 19059063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current evidence for a genetic modulation of the response to analgesics.
    Lötsch J; Geisslinger G
    Pain; 2006 Mar; 121(1-2):1-5. PubMed ID: 16472919
    [No Abstract]   [Full Text] [Related]  

  • 6. [Genetic polymorphisms and human sensitivity to pain and opioids].
    Nishizawa D; Nagashima M; Satoh Y; Tagami M; Ikeda K
    Masui; 2009 Sep; 58(9):1093-101. PubMed ID: 19764431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of genetic factors on opioid action.
    Kosarac B; Fox AA; Collard CD
    Curr Opin Anaesthesiol; 2009 Aug; 22(4):476-82. PubMed ID: 19502975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.
    Crews KR; Monte AA; Huddart R; Caudle KE; Kharasch ED; Gaedigk A; Dunnenberger HM; Leeder JS; Callaghan JT; Samer CF; Klein TE; Haidar CE; Van Driest SL; Ruano G; Sangkuhl K; Cavallari LH; Müller DJ; Prows CA; Nagy M; Somogyi AA; Skaar TC
    Clin Pharmacol Ther; 2021 Oct; 110(4):888-896. PubMed ID: 33387367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetics and variability in opioid response.
    Stamer UM; Bayerer B; Stüber F
    Eur J Pain; 2005 Apr; 9(2):101-4. PubMed ID: 15737794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Genetic variation-- important for the clinical effect of opioids?].
    Klepstad P; Dale O; Borchgrevink PC; Kaasa S; Skorpen F
    Tidsskr Nor Laegeforen; 2005 Oct; 125(19):2655-8. PubMed ID: 16215614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Implication of genetic polymorphism on neuropathic pain].
    Iseki M; Sato-Takeda M
    Masui; 2009 Sep; 58(9):1112-21. PubMed ID: 19764434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the genetic determinants of pain and pain management.
    Miaskowski C
    Semin Oncol Nurs; 2009 May; 25(2 Suppl 1):S1-7. PubMed ID: 19447317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pain management of musculoskeletal injuries in children: current state and future directions.
    Ali S; Drendel AL; Kircher J; Beno S
    Pediatr Emerg Care; 2010 Jul; 26(7):518-24; quiz 525-8. PubMed ID: 20622635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics of opioids.
    Somogyi AA; Barratt DT; Coller JK
    Clin Pharmacol Ther; 2007 Mar; 81(3):429-44. PubMed ID: 17339873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pain and genetics.
    Fernandez Robles CR; Degnan M; Candiotti KA
    Curr Opin Anaesthesiol; 2012 Aug; 25(4):444-9. PubMed ID: 22732422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of CYP2D6 and OPRM1 pharmacogenetic testing for opioid therapy.
    Reynolds KK; Ramey-Hartung B; Jortani SA
    Clin Lab Med; 2008 Dec; 28(4):581-98. PubMed ID: 19059064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fundamental Considerations for Genetically-Guided Pain Management with Opioids Based on CYP2D6 and OPRM1 Polymorphisms.
    Ruano G; Kost JA
    Pain Physician; 2018 Nov; 21(6):E611-E621. PubMed ID: 30508992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication.
    Stamer UM; Stüber F; Muders T; Musshoff F
    Anesth Analg; 2008 Sep; 107(3):926-9. PubMed ID: 18713907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complicated pain management in a CYP450 2D6 poor metabolizer.
    Foster A; Mobley E; Wang Z
    Pain Pract; 2007 Dec; 7(4):352-6. PubMed ID: 17986163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.